Our research center is dedicated to the research, development and progress of new therapies for a number of different disorders that will improve the quality of life for patients. We are continually enrolling patients of all ages in research studies. We may have a study that is right for you! Please look below at our currently enrolling studies. If interested, please call us at 949-347-8700 x1800.
Currently Enrolling Studies
Asthma
Asthma - Currently Enrolling
- AstraZeneca D5982C00008: A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS).
- GSK 206867: A Phase 3, 24-Week, Randomized, Double-Blind, Parallel-Group Bayesian Dynamic Borrowing Study Comparing the Efficacy, Safety, Tolerability, and Pharmacokinetics of Fluticasone Furoate/Umeclidinium bromide/Vilanterol trifenatate (FF/UMEC/VI) with Fluticasone Furoate/Vilanterol trifenatate (FF/VI) in 12-17-year-old Participants with Inadequately Controlled Asthma on Stable Maintenance Therapy with ICS/LABA (ARIA).
Chronic Cough
Chronic Cough - Currently Enrolling
- Bellus BUS-P3-01: A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough, Including Unexplained Chronic Cough (CAML1).
Food Allergy
Food Allergy - Currently Enrolling
- DBV V712-306: A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250µg in 4-7-year-old Children with Peanut Allergy (VITESSE).
Urticaria
Chronic Spontaneous Urticaria - Currently Enrolling
- Allakos AK002-027: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab in Adult Subjects with H-1 Antihistamine Refractory Chronic Spontaneous Urticaria.
Active Non-Enrolling Studies
Atopic Dermatitis
Atopic Dermatitis - Active Non-Enrolling
- AbbVie M16-045: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis.
- Pfizer B7451015: A Phase 3 Multicenter, Long-Term Extension Study Investigating the Efficacy and Safety of Abrocitinib, with or without Toical Medications Administered to Subjects Aged 12 Years and Older with Moderate to Severe Atopic Dermatitis.
- Regeneron R668-AD-1434: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to <18 Years of Age with Atopic Dermatitis.
Food Allergy
Food Allergy - Active Non-Enrolling
- Alladapt ADP101-MA-02: An Open-Label Extension Study Evaluating the Safety and Efficacy of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Encore Study).
Completed Studies
Allergic Rhinitis and Rhinoconjunctivitis
Allergic Rhinitis and Rhinoconjunctivitis - Completed
- Stallergenes Greer SL75.14:A Randomized, double-blind, placebo-controlled, multi-center study of the Efficacy and Safety of STG320 sublingual tablet of house dust mite (HDM) allergen extracts in adults and adolescents with HDM-associated allergic rhinitis
- Glenmark GSP 301-305: A Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination GSP 301 Nasal Spray Compared with Placebo Nasal Spray in Pediatric Subjects (aged 6 to under 12 years) With Seasonal Allergic Rhinitis (SAR)
- ALK-Abelló A/S P05607: A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma
- Circassia TH005:A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis
- Regeneron R1908-1909-ALG-2102: A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients with Allergic Rhinitis who Live with a Cat to Assess the Efficacy and Safety of Anti-Fel D 1 Antibodies During Natural Cat Exposure in the Home.
Asthma
Asthma - Completed
- Cipla U-FS-MU-AS3120: A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, 4-week Clinical Endpoint Bioequivalence Study Comparing Fluticasone Propionate/Salmeterol 100/50 µg inhalation powder (Cipla Ltd., India) with Advair®Diskus 100/50 µg (GlaxoSmithKline, USA) in Asthma Patients
- Gossamer GB001-2001: A Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 as maintenance therapy in adult subjects with moderate to severe asthma
- Amphastar API-A008-BE-PD: A Randomized, Single-Dose, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Crossover PD Study
- TEVA TPI-18-03: A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg in Adult Subjects with Asthma
- AstraZeneca D3250C00045: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg SC in Patients with Severe Asthma Uncontrolled on Standard of Care Treatment
- Kindeva CSP-07-000034: Randomized, Single Blind, Parallel Group, Placebo Controlled, Multidose Study Comparing the Therapeutic Equivalence of a 3M Budesonide/Formoterol Fumarate Inhaler and a Symbicort® Reference Inhaler in Adult Subjects With Asthma
- Hoffmann-La Roche GB28689: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
- Teva BDB-AS-302: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Pediatric Patients 4 Through 11 Years of Age With Persistent Asthma
- AstraZeneca D589GC00003: A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg, 2 Actuations Twice Daily, and Symbicort pMDI 80/4.5 μg, 2 Actuations Twice Daily, Compared With Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to <12 Years With Asthma
- Teva FSS-AS-30003: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma
- Merck 0887A-087: A Phase III, Randomized, Active-Controlled, Parallel-Group Clinical Trial to Study the Efficacy and Long-Term Safety of Mometasone Furoate/Formoterol Fumarate (MF/F, MK-0887A [SCH418131]), Compared With Mometasone Furoate (MF, MK-0887 [SCH032088]), in Children With Persistent Asthma
- Sanofi EFC13579: A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma
- GSK 201832: A Randomised, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Adolescent and Adult Subjects With Asthma and Exercise-Induced Bronchoconstriction
- Teva FSS-AS-30017: A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy
- Teva FSS-AS-305: A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older With Persistent Asthma
- Teva BDB-AS-30039: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) at 320 or 640 mcg/Day in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma
- Teva FSS-AS-301: A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Low-dose or or Mid-dose Inhaled Corticosteroid Therapy
- AstraZeneca D5180C00007: A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)
- West-Ward Columbus FLSA-P100/50-PVCL-2: A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 μg and Salmeterol Xinafoate 50 μg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
- Novartis CQAW039A2316: A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
- Teva ACT-2015-075-0AA: A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter, Multinational Study to Compare the Therapeutic Equivalence of a Budesonide 80 μg/Formoterol Fumarate Dihydrate 4.5 μg Inhalation Aerosol (Manufactured by Catalent for Watson Laboratories Inc.) to Symbicort® (Budesonide 80 μg/Formoterol Fumarate Dihydrate 4.5 μg Inhalation Aerosol) (Manufactured by AstraZeneca) in Adolescent and Adult Patients With Asthma
- Novartis CQAW039A2316: A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
- Novartis CCSJ117A12201C: A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Study to Assess the Efficacy and Safety of CSJ117, when Added to Existing Asthma Therapy in Patients ≥18 Years of Age with Severe Uncontrolled Asthma.
- Suzhou Connect CBP-201-WW002: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Efficacy and Safety Study of CBP-201 in Adult Patients with Moderate to Severe Persistent Asthma with Type 2 Inflammation.
Atopic Dermatitis
Atopic Dermatitis - Completed
- AbbVie M16-045: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
- Incyte INCB 18424-304: A Phase 3, Double-Blind, Randomized, 8-week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults with Atopic Dermatitis
- Pfizer B7451029: A Phase 3 Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Center Study Investigating The Efficacy and Safety of PF-04965842 and Dupilumab in Comparison with Placebo in Adult Subjects on Background Topical Therapy, With Moderate to Severe Atopic Dermatitis.
- Regeneron R668-AD-1652: A Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly with Topical Corticosteroids in Patients ≥ 6 Years To <12 Years of Age with Severe Atopic Dermatitis
- Pfizer B7451036: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating The Efficacy and Safety of PF-04965842 Co-Administered With Background Medicated Topical Therapy in Adolescent Participants 12 to < 18 years of age with Moderate to Severe Atopic Dermatitis.
- Hoffmann-La Roche GS29735: An Open-Label Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Persistent, Moderate to Severe Atopic Dermatitis
- Regeneron R668-AD-1314: A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
- Dermavant DMVT-505-3101: A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults
- Dermavant DMVT-505-3103: An Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects with Atopic Dermatitis
- Incyte INCB 18424-304: A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis (TRuE-AD2).
- Incyte INCB 18424-305: A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis (TRuE-AD3).
Chronic Cough
Chronic Cough - Completed
- Vyne MTI-110: A randomized, double-blind, placebo-controlled study of the efficacy, safety and tolerability of serlopitant for the treatment of refractory chronic cough
- Attenua ATA101-PN-001: A Dose Escalation Study to Assess the Efficacy and Safety of ATA-101 in Subjects with Refractory Chronic Cough
- Bellus BUS-P2-02: A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallet-Arm Phase 2b Study to Evaluate the Efficacy and Safety of Multiple Doses of BLU-5937 in Adult Participants With Refractory Chronic Cough
Food Allergy
Food Allergy - Completed
- Aimmune ARC007: Real World AR101 Market Supporting Experience Study in Peanut Allergic Children Ages 4 to 17 years (RAMSES)
- Regeneron R668-ALG-16114: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study In Pediatric Subjects With Peanut Allergy To Evaluate The Efficacy And Safety Of Dupilumab As Adjunct To AR101 (Peanut Oral Immunotherapy).
- Nestle 16.16.CLI: Evaluation of Hypoallergenicity of a New Extensively Hydrolyzed Formula
- DBV REALISE V712-EAP01: Long-Term Assessment of Safety and Therapeutic Benefit of Viaskin Peanut Epicutaneous Treatment in Peanut-Allergic Children: A 6-month Randomized, Double-Blind, Placebo-Controlled Phase III Study Followed by An Open Label Active Treatment (REALISE Study)
- Aimmune ARC003: Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
- Novartis CQGE031G12301: A 52 week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Children and Adult Patients with Peanut Allergy.
- Alladapt ADP101-MA-01: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Harmony Study).
- COUR CNP-201-5.002: A Phase 1b/2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of CNP-201 in Subjects Ages 16-55 with Peanut Allergy.
Migraines
Migraines - Completed
- Zosano CP-2016-001: Randomized, double-blind, multi-center, parallel-group, dose-ranging, comparison of the safety and efficacy of the ZP-Zolmitriptan intracutaenous microneedle systems to placebo for the acute treatment of migraine.
Nasal Polyps
Nasal Polyps - Completed
- Hoffmann-La Roche GA39688: A Phase III, randomized, multicenter, double-blind, placebo-controlled clinical trial of omalizumab in patients with Chronic Rhinosinusitis with Nasal Polyps
Urticaria
Urticaria - Completed
- Novartis CQGE031C2201: A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
- Genentech GS39684: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot and Dose-Ranging Study of GDC-0853 in Patients With Refractory Chronic Spontaneous Urticaria (CSU).
- Novartis CLOU064A2201: A multicenter, randomized, double-blind, placebo-controlled Phase 2b dose- finding study to investigate the efficacy, safety and tolerability of LOUD064 in adult chronic spontaneous urticarial patients inadequately controlled by H1-antihistamines
- AstraZeneca D3259C00001: A Phase 2b Multinational, Randomized, Double-Blind, Parallel-Group, 24-week Placebo-controlled Study with 28-week Extention to Investigtae the Use of Benralizumab in Patients with Chronic Spontaneous Urticaria Who are Symptomatic Despite the Use of Antihistamines (ARROYO)
- Amgen 20190194: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria
- Genentech ML29510: XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
- Novartis CQGE031C2201: A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
